[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"GT Metabolic Solutions, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":143},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,69,90,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":41},"100637455","magnet-system-gastric-outlet-obstruction-study-100637455",false,"NCT07609511","Magnet System Gastric Outlet Obstruction Study","Creation of Magnetic Compression Gastroenterostomy Using the GT Metabolic Solutions Magnet System in Adults With Gastric Outlet Obstruction (GOO): Magnet System GOO Study","Inclusion Criteria:\n\n* Gastric outlet obstruction (GOO) and indicated for a gastroenterostomy, per the discretion of the treating investigator.\n* If a child-bearing female, subject must commit to not becoming pregnant and agree to use contraception for the duration of the study.\n* Willing and able to comply with protocol requirements and provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the gastroenterostomy procedure.\n* If GOO due to malignant neoplasm:\n* Baseline Eastern Cooperative Oncology Group (ECOG) \\> 2 and\u002For Karnofsky Performance score \\\u003C 30\n* Gastric or intestinal cancer or malignant infiltration precluding creation of a magnetic compression anastomosis (per investigator discretion)\n* Coagulation disorders, on continuous or complete anticoagulation, or other conditions associated with high risk of bleeding and not correctable or manageable, precluding creation of a magnetic compression anastomosis (per investigator discretion)\n* Any anomaly precluding orogastric access by endoscope and catheters, and manipulation techniques.\n* Implantable pacemaker or defibrillator.\n* Woman who is either pregnant or breast feeding.\n* Any comorbidity or current status of subject's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the subject medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the Magnets.\n* Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target Magnet deployment sites.\n* Expected need for Magnetic Resonance Imaging (MRI) within the first 2 months after the procedure.\n* Any anomaly preventing\u002Fcontraindicating endoscopic or laparoscopic access and procedures.\n* Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure.\n* Unable to comply with the follow-up schedule and assessments.\n* Known allergies to the device components or contrast media.\n* Currently participating in another clinical research study with an investigational drug or medical device.\n* Any condition that, in the investigator's opinion, may preclude completion of follow-up assessments through Day 90 (e.g., a medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, or poor compliance with treatment regimen.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","Evaluate the performance and safety of the GT Metabolic Magnet System to create side-to-side gastroenteral magnetic compression anastomosis (gastroenterostomy).",[26],"Gastric Outlet Obstruction",[28,29],"Magnet System","GT Metabolic Solutions, Inc.","NOT_YET_RECRUITING","2026-05-21",{"date":33,"type":34},"2026-05-27","ACTUAL",{"date":36,"type":20},"2026-07",{"date":38,"type":20},"2026-12",{"name":29,"class":40},"INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100626137","creation-of-compression-anastomosis-using-the-gt-metabolic-magnet-system-100626137","NCT07431723","Creation of Compression Anastomosis Using the GT Metabolic Magnet System","Creation of Compression Anastomosis Using the GT Metabolic Magnet System as Either the Primary or the First Stage of Colorectal Surgery (MagCR Study)","MagCR","Inclusion Criteria:\n\n* Indicated for colorectal surgery requiring anastomosis within the colon or colon and distal small bowel (i.e., colocolic, colorectal, rectalrectal, ileocolic, or ileorectal) performed side-to-side or endto-end with ileostomy\n* Participant has been informed of the nature of the study and agrees to its provisions, complying with study required testing, medications, follow-up visits, and has provided written informed consent.\n\nExclusion Criteria:\n\n* High frailty index, with a score of ≥ 3 on the five-item modified frailty index (mFI-5).\n* Severe Sarcopenia as determined by the investigator.\n* Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the procedure, including scarring and abnormal anatomy at the target anastomosis sites.\n* Any anomaly precluding orogastric access by colonoscope and catheters, and manipulation techniques.\n* Any anomaly preventing \u002F contraindicating colonoscopic or laparoscopic access and procedures.\n* Implantable pacemaker or defibrillator (and\u002For other devices that may be impacted by or interfere with the Magnet System).\n* Psychiatric disorder, except well-controlled depression with medication for \\> 6 months.\n* Pregnant, lactating, or planning pregnancy during the clinical investigation.\n* Any comorbidity or current status of participant's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the participant medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the Magnets.\n* Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target Magnet deployment site.\n* Expected need for Magnetic Resonance Imaging (MRI) within the first 2 months post-procedure.\n* Any surgical or interventional procedure (including planned and\u002For scheduled) within the period of 30 days prior to and 30 days following the study procedure.\n* Any stroke\u002FTransient Ischemic Attack (TIA) ≤ 6 months prior to consent.\n* Requires chronic anticoagulation therapy (except aspirin).\n* Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure.\n* Current tobacco \u002F nicotine product usage or recent product cessation ≤ 3 months prior to informed consent.\n* Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media.\n* Participants with comorbidities that are likely to result in a life expectancy ≤ 12 months.\n* Currently participating in an investigational drug or another device study that has not reached its primary endpoint\n* Presence of other anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.","75 Years",{"count":52,"type":20},50,[23],"Evaluate the performance and safety of the Magnet System to create anastomoses throughout the large bowel and between the large and distal small bowel.",[56,57],"Anastomosis, Functional","Colorectal",[28,29],"RECRUITING","2026-05-18",{"date":62,"type":34},"2026-05-19",{"date":64,"type":34},"2026-02-16",{"date":66,"type":20},"2028-02",{"name":29,"class":40},2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100617319","gt-metabolic-magnet-system-in-adults-with-gastrointestinal-disorders-100617319","NCT07317076","GT Metabolic Magnet System in Adults With Gastrointestinal Disorders","Compression Anastomosis Using the GT Metabolic Magnet System in Adults With Gastrointestinal Disorders (GT Metabolic Magnet System Study)","Inclusion Criteria:\n\n* Indicated for gastrointestinal surgery requiring a gastric and\u002For small bowel anastomosis, without need for immediate lumen patency, and meets one of the following criteria:\n\n  1. Superior mesenteric artery syndrome (SMAS); OR\n  2. Gastric outlet obstruction (GOO); OR\n  3. Partial small bowel obstruction.\n* Meets the surgical clearance requirements as governed by the investigator's institution.\n* If a child-bearing female, subject must commit to not becoming pregnant and agree to use contraception for the duration of the study.\n\nExclusion Criteria:\n\n* Other gastrointestinal or abdominal surgeries planned concurrently or within the study follow-up period (e.g., bariatric surgery such as sleeve gastrectomy).\n* Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the anastomosis or study procedure, including scarring and abnormal anatomy at the anastomosis sites.\n* Any anomaly precluding gastrointestinal access by gastroscope \u002F endoscope, catheters, and associated manipulation techniques for device placement.\n* Any condition or disease that precludes laparoscopic surgery.\n* Implantable pacemaker, defibrillator, other active and\u002For metallic implant that may interfere with or be adversely impacted by a temporary magnetic implant (Magnet System) and associated procedures.\n* Unhealed ulcers, bleeding lesions, tumor, diseased tissue or any other lesion at or distal to the target Magnet deployment sites.\n* Any need for immediate lumen patency while the anastomosis is formed.\n* History of prior or current malignancy.\n* Expected need for Magnetic Resonance Imaging (MRI) within the first 3 months post-procedure (or before if Magnet expulsion is confirmed radiologically).\n* Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media.\n* Pregnant, lactating, or planning pregnancy during the clinical investigation and follow up period.\n* Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study.\n* Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements.",{"count":77,"type":20},35,[23],"Evaluate the performance and safety of the GT Metabolic Magnet System for the creation of side-to-side compression anastomosis in the stomach and\u002For small bowel in conditions requiring an anastomosis as part of the underlying clinical treatment.",[26,81,82],"Small Bowel Obstruction","Superior Mesenteric Artery Syndrome",[28,29],{"date":62,"type":34},{"date":86,"type":34},"2025-12-09",{"date":88,"type":20},"2026-11",{"name":29,"class":40},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":106,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":41},"100617322","side-to-side-duodeno-ileostomy-versus-semaglutide-in-adults-with-obesity-and-type-2-diabetes-100617322","NCT07317115","Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)","MAGvMED","Inclusion Criteria:\n\n* Body Mass Index (BMI) between 30 - 40 kg\u002Fm2 and qualifies for obesity treatment at the discretion of the treating investigator (i.e., must be assessed to qualify for both surgery and medication treatment to justify randomization).\n* Type 2 diabetes (T2D defined as HbA1c ≥ 6.5%).\n* Participant agrees to refrain from additional metabolic and bariatric (MBS) or reconstructive surgery that would affect body weight for the duration of the study.\n* Participant agrees to refrain from taking any additional semaglutide-containing or other GLP-1RA medication for the duration of the study, regardless of randomization assignment (i.e., Surgery or Medication).\n\nParticipant has been informed of the nature of the study and is willing and able to comply with requirements, including randomization, and provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Meets any of the contraindications for either treatment arm (Surgery: Magnet System; or Medication: semaglutide), thereby prohibiting randomization\n* Current or previous metabolic and bariatric surgery (MBS) treatment in the previous 12 months (e.g., sleeve gastrectomy, intragastric balloons, adjustable gastric banding).\n* Taking or treated with semaglutide, semaglutide-containing medications, or any other GLP-1RA medication in the previous 12 months.\n* Pregnant, lactating or planning pregnancy during the clinical study and follow-up period.\n* Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study.\n* Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, would contraindicate either treatment arm or could limit the participant's ability to participate in the clinical study or to comply with follow-up requirements.",{"count":99,"type":20},20,[23],"Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).",[103,104,105],"Obesity (Disorder)","Obesity & Overweight","Type 2 Diabetes (T2DM)",[28,107,29],"Semaglutide",{"date":62,"type":34},{"date":110,"type":34},"2026-03-18",{"date":112,"type":20},"2028-06",{"name":29,"class":40},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":124,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":5},"100587450","magdi-us-registry-100587450","NCT06928545","MagDI U.S. Registry","Post-Market Assessment of the Incidence and Severity of Internal Hernia and Bowel Obstruction at One Year Following Use of the MagDI System to Create Side-to-Side Duodeno-Ileal Magnetic Compression Anastomoses (MagDI US Registry)","Inclusion Criteria:\n\n1. \\>21 years of age, at the time of informed consent.\n2. Body Mass Index (BMI) between 30-50 kg\u002Fm2.\n3. Indicated for a side-to-side duodeno-ileal anastomosis and is treated with the MagDI System at a U.S. registry center.\n4. Participant has been informed of the nature of the registry.\n\nExclusion Criteria:\n\n1\\. Participant does not provide informed consent to be enrolled and followed in the registry.","22 Years",{"count":123,"type":20},106,"12 Months","OBSERVATIONAL","Assess the incidence and severity of internal hernia and bowel obstruction at one year in a U.S. population following use of the MagDI System to create side-to-side duodeno-ileal anastomoses.",[128,129,130],"Anastomosis, Surgical","Internal Hernia","Bowel Obstruction",[132,133,134],"GT Metabolic","MagDI System","Magnetic Anastomosis","2026-02-19",{"date":137,"type":34},"2026-02-20",{"date":139,"type":34},"2025-03-28",{"date":141,"type":20},"2027-04",{"name":29,"class":40},""]